Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NPS 1776 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | PLACEBO |
| 2 | EXPERIMENTAL | 400 mg 1776 powder |
| 3 | EXPERIMENTAL | 1776 (800 mg) |
| Name | Type | Description |
|---|---|---|
| NPS 1776 (800 mg) | DRUG | NPS 1776 (800 mg) powder |
| PLACEBO | DRUG | Placebo in non-carbonated fruit flavored drink (150 ml) |
| NPS 1776 (400 mg) | DRUG | NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink |
Inclusion Criteria: 1. Diagnosis of migraine for at least a year prior to screening. 2. Experiences 2-10 migraine headaches per month (with at least 24 hours between episodes) and no more than 15 headache days per month in the 3 months prior to screening. 3. Ability and willingness to arrive at the...
NPS 1776 is an investigational small molecule being studied for the acute treatment of migraine headaches. It is a Phase 2 drug candidate in the neurology therapeutic area. As of the available data, it is not approved and remains in clinical development.
NPS 1776 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The drug is a small molecule in Phase 2 clinical development for the acute treatment of migraine headaches.
NPS 1776 is in Phase 2 clinical development. It is an investigational drug for the acute treatment of migraine headaches and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
NPS 1776 has one completed Phase 2 clinical trial, identified as NCT00172094, titled 'Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches.' The trial enrolled 189 participants in the United States and was randomized, double-blind, and placebo-controlled.
NPS 1776 is not FDA approved. It is an investigational drug in Phase 2 clinical development for the acute treatment of migraine headaches. The available data shows one completed Phase 2 trial, but no approval status has been established.